Get the Stockscreener App
2.59
2.63%
-0.07
Black Diamond Therapeutics Inc stock is traded at $2.59, with a volume of 708.42K.
It is down -2.63% in the last 24 hours and up +4.44% over the past month.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
See More
Previous Close:
$2.66
Open:
$2.6
24h Volume:
708.42K
Relative Volume:
0.63
Market Cap:
$147.27M
Revenue:
-
Net Income/Loss:
$-82.44M
P/E Ratio:
-1.3777
EPS:
-1.88
Net Cash Flow:
$-66.75M
1W Performance:
-12.79%
1M Performance:
+4.44%
6M Performance:
-1.15%
1Y Performance:
-57.26%
1-Day Range:
$2.52
$2.625
1-Week Range:
$2.52
$3.08
52-Week Range:
$1.195
$6.75
Black Diamond Therapeutics Inc Stock (BDTX) Company Profile
Name
Black Diamond Therapeutics Inc
Sector
Industry
Phone
617-417-5868
Address
ONE MAIN STREET, 14TH FLOOR, CAMBRIDGE, MA
Compare BDTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BDTX
Black Diamond Therapeutics Inc
|
2.59 | 151.25M | 0 | -82.44M | -66.75M | -1.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Black Diamond Therapeutics Inc Stock (BDTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-01-25 | Resumed | Raymond James | Outperform |
| Jul-31-24 | Initiated | Raymond James | Outperform |
| Jul-14-23 | Initiated | Piper Sandler | Overweight |
| Jun-30-23 | Upgrade | Stifel | Hold → Buy |
| Jun-28-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-27-23 | Upgrade | Wedbush | Neutral → Outperform |
| Mar-29-22 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-22-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-30-21 | Initiated | Stifel | Hold |
| Jan-07-21 | Initiated | Wedbush | Outperform |
| Nov-24-20 | Initiated | Berenberg | Buy |
| May-04-20 | Initiated | H.C. Wainwright | Buy |
| Feb-24-20 | Initiated | Canaccord Genuity | Buy |
| Feb-24-20 | Initiated | Cowen | Outperform |
| Feb-24-20 | Initiated | JP Morgan | Overweight |
| Feb-24-20 | Initiated | Jefferies | Buy |
View All
Black Diamond Therapeutics Inc Stock (BDTX) Latest News
Has Black Diamond Therapeutics Inc. formed a bullish divergenceReal Time Trade Execution Alert Plan - Newser
Clarus (CLAR) Q2 Loss Beats Estimates - The Motley Fool
Is Black Diamond Therapeutics Inc. stock overvalued or undervaluedReal Time Tracker For Fast Growth - jammulinksnews.com
What makes Black Diamond Therapeutics Inc. stock price move sharplyValue Investing Data Feed For Beginners - jammulinksnews.com
What is the risk reward ratio of investing in Black Diamond Therapeutics Inc. stockBest Dividend Updates For Beginners - jammulinksnews.com
What are the technical indicators suggesting about Black Diamond Therapeutics Inc.Low Risk Guidance That Work - jammulinksnews.com
Historical volatility pattern of Black Diamond Therapeutics Inc. visualizedEntry Timing with Downside Risk Analysis - Newser
Sentiment analysis tools applied to Black Diamond Therapeutics Inc.Risk-Managed Trade Alerts for Consistency - Newser
Top Risks to Consider Before Buying Black Diamond Therapeutics Inc. StockBuy Opportunity Forecast for Fast Traders - Newser
When is the best time to exit Black Diamond Therapeutics Inc.7-Day Equity Return Range Forecast Model - Newser
Price action breakdown for Black Diamond Therapeutics Inc.Swing Reversal Forecast Based on Patterns - Newser
How Black Diamond Therapeutics Inc. stock performs during market volatilityCapital Protection Strategy With Risk Analysis - Newser
Will Black Diamond Therapeutics Inc. Stock Benefit from AI and Green Energy TrendsBuy and Hold Position Summary Review - Newser
How does Black Diamond Therapeutics Inc. generate profit in a changing economyAI Powered Growth Plan For 2025 - jammulinksnews.com
Chart based analysis of Black Diamond Therapeutics Inc. trendsFree Top Gaining Picks With Entry Signals - Newser
How to use a screener to detect Black Diamond Therapeutics Inc. breakoutsFree Entry Plan for Oversold Reversal Stocks - Newser
Published on: 2025-07-29 16:50:08 - metal.it
Technical Charts Suggest Momentum Shift in Black Diamond Therapeutics Inc. - metal.it
Using data tools to time your Black Diamond Therapeutics Inc. exitBuy Signal Forecast With Short-Term Data - Newser
Why Black Diamond Therapeutics Inc. stock attracts strong analyst attentionStock Holding Strategy Long-Term Summary Sheet - Newser
Quant Funds Rotate Into Black Diamond Therapeutics Inc. StockHigh Win Rate Trading Opportunities Detected - metal.it
What is the dividend policy of Black Diamond Therapeutics Inc. stockUnlock expert trading strategies for growth - jammulinksnews.com
Does Black Diamond Therapeutics Inc. stock perform well during market downturnsMarket-crushing profits - jammulinksnews.com
Using portfolio simulators with Black Diamond Therapeutics Inc. includedFree Capital Preserving Trade Plan Templates - Newser
Is Black Diamond Therapeutics Inc. a Top Dividend Stock to Watch in 2025Free Profit Target Stock Opportunity Monitor - Newser
What institutional investors are buying Black Diamond Therapeutics Inc. stockChart Pattern Guidance To Watch Now - jammulinksnews.com
What are analysts’ price targets for Black Diamond Therapeutics Inc. in the next 12 monthsInvest smarter with expert trading signals - jammulinksnews.com
What are the latest earnings results for Black Diamond Therapeutics Inc.Capitalize on momentum-driven investment opportunities - jammulinksnews.com
What are Black Diamond Therapeutics Inc. company’s key revenue driversMaximize returns with disciplined trading approaches - jammulinksnews.com
Is Black Diamond Therapeutics Inc. Stock a Good Fit for Conservative InvestorsHigh Accuracy Alerts - metal.it
Is Black Diamond Therapeutics Inc. a growth stock or a value stockMaximize returns with timely market signals - jammulinksnews.com
Competitive Positioning of Black Diamond Therapeutics Inc.: Is It Leading or LaggingMinimized Risk Maximum Return - Newser
Is Black Diamond Therapeutics Inc. a good long term investmentUnrivaled growth potential - PrintWeekIndia
Black Diamond Therapeutics Inc. Stock Analysis and ForecastSignificant capital appreciation - PrintWeekIndia
What analysts say about Black Diamond Therapeutics Inc. stockFastest-growing stock picks - PrintWeekIndia
What drives Black Diamond Therapeutics Inc. stock priceTriple-digit growth rates - jammulinksnews.com
Black Diamond Therapeutics Inc Stock (BDTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):